Description
Urgo Start plus
Description
Hydro-detergent dressing composed of poly-absorbent gelling fibres in polyacrylate with an acrylic core, which guarantee a cleansing and debridement capacity of the lesion base (from slough, fibrin and debris) with a TLC-NOSF healing matrix (lipid-colloidal technology with potassium sucrose octasulfate).
UrgoStart Plus Pad is indicated for the treatment of non-infected, exuding wounds, specifically long-standing or potentially long-standing wounds (e.g. vascular wounds, diabetic foot wounds, pressure ulcers), at all stages of the healing process.
In contact with the base of the lesion, the extremely hydrophilic polyacrylate hydro-detergent fibres absorb the exudate, leading to swelling and subsequent gelation of the fibres themselves, maintaining the moist environment essential for healing and the ability to stimulate a mild autolytic debridement. In the meantime, the fibres mechanically disintegrate and attract with an electrostatic mechanism slough, fibrin, debris and bacteria, trapping them in the dressing and limiting bacterial proliferation, while allowing continuous but progressive cleansing and debridement of the base of the lesion and protecting the perilesional skin, thanks to a vertical absorption mechanism.
Furthermore, the gelation of the fibres allows the dressing not to adhere to the base of the lesion, allowing for atraumatic removal for the tissues and without pain for the patient, while maintaining a high cohesion of the dressing which allows removal in a single piece.
Finally, the composition of the dressing allows for the management of minor bleeding, thanks to its hemostatic properties.
The micro-adherent TLC layer in contact with the wound exudate, sees the formation of a lipid-colloidal gel, thanks to the interaction between the hydrocolloidal particles and Vaseline, which creates a moist environment favorable to the wound healing process, capable of stimulating the proliferation of key cells for tissue repair. The TLC matrix has been shown to stimulate the proliferation of fibroblasts by 70% and to increase the synthesis of hyaluronic acid and collagen production by 53% and 80% respectively. The lipid substances of the TLC matrix contribute to the non-adherence of the dressing to the base of the wound with consequent atraumatic dressing changes for the newly formed tissues and without pain for the patient. The ease of application and removal of the dressing, in addition to its effectiveness, has also been evaluated in clinical studies on thousands of patients.
Furthermore, the presence of sucrose octasulfate in the dressing gives it metalloproteinase modulating properties, allowing for better healing rates than the neutral dressing, with a consequent reduction in healing times, to the point of having allowed its inclusion in the NICE and IWGDF recommendations as a recommended dressing for the treatment of lower limb and diabetic foot lesions, by virtue of its cost-effectiveness.
In contact with wound exudate, the TLC-NOSF technology of UrgoStart Plus Pad gels. Thanks to this hydrophilic gelation and the presence of lipophilic substances in the composition, this technology:
- absorbs components of wound exudate, including enzymes called matrix metalloproteinases (MMPs), elevated levels of which have been linked to delayed healing of chronic wounds;
- maintains the moist environment necessary for wound healing.
Promoting debridement/cleansing:
- the fibers trap fibrin, slag, debris and cause them to detach from the wound when the dressing is removed.
Hemostatic properties:
- in case of small hemorrhages, the adsorption of plasma proteins by the polyacrylate fibers leads to the activation of coagulation and the adhesion of platelets, which initiate and have a synergistic effect on blood clotting.
Comfort promotion:
- the device is soft and flexible and the gelled TLC-NOSF technology lubricates the contact surface. These properties make the device conformable, reduce friction and make the device comfortable.
To ensure atraumatic removal of the lesion and peri-lesional skin and to allow easy removal:
- the moist environment prevents exudate from drying out. In addition, the gelled TLC-NOSF technology lubricates the contact surface, preventing the dressing from sticking to the wound bed when removed, so as not to resist removal and not to cause pain to the patient.
How to use
- The microadherent layer of UrgoStart may adhere to latex surgical gloves. It is therefore recommended to avoid contact or use sterile forceps.
- Cleanse the lesion with saline solution.
- If using an antiseptic, rinse the wound with saline solution before applying UrgoStart Plus Pad and dry the periwound skin.
- UrgoStart can be cut with sterile scissors to fit the size of the wound.
- The use of UrgoStart Plus does not replace mechanical debridement, if necessary.
- Remove the transparent protective films.
- Apply the micro-adherent side of UrgoStart Plus to the lesion.
- Keep the dressing in place with a secondary dressing, adhesive plaster or a bandage, including a compressive one if prescribed.
- UrgoStart Plus Pad may be left in place for up to 7 days, depending on clinical conditions and local protocol.
Warnings
Contraindications:
- known sensitivity to the medication or to one of its components;
- malignant lesions;
- fistula lesions;
- lesions from epidermiolysis bullosa;
- necrotic lesions.
- If clinical signs of local infection appear, treatment should be changed to antimicrobial therapy, according to medical advice.
- In case of atypical ulcers with signs of induration or excessive granulation, it is recommended to use UrgoStart Plus Pad only after having verified the absence of degeneration associated with the lesion, in order not to delay the diagnosis.
- At the beginning of treatment, a stinging/painful sensation may occur as a result of the activation of the healing process. This rarely leads to discontinuation of therapy.
- In the absence of clinical data as a first-line treatment of acute lesions and in the treatment of Epidermolysis Bullosa (even in case of long-standing lesions), the use of UrgoStart Plus Pad is not recommended.
- UrgoStart Plus Pad should not be used in a hyperbaric chamber.
- In the absence of specific clinical data, UrgoStart is not recommended for the treatment of lesions on children, pregnant or breastfeeding women.
- Concomitant use of creams, ointments or emulsions is not recommended.
- Do not use if package is damaged.
- Ensure that the sterile protection is intact before use. Do not use the dressing if damaged.
- Single use, do not resterilize the dressing.
Conservation
Store below 25°C and away from sources of light and humidity.
Validity with intact packaging: 36 months.
Format
Available in packs of 10 in sizes 6x6 cm and 10x10 cm.
Code 602892
Code 602893
Hydro-detergent dressing composed of poly-absorbent gelling fibres in polyacrylate with an acrylic core, which guarantee a cleansing and debridement capacity of the lesion base (from slough, fibrin and debris) with a TLC-NOSF healing matrix (lipid-colloidal technology with potassium sucrose octasulfate).
UrgoStart Plus Pad is indicated for the treatment of non-infected, exuding wounds, specifically long-standing or potentially long-standing wounds (e.g. vascular wounds, diabetic foot wounds, pressure ulcers), at all stages of the healing process.
In contact with the base of the lesion, the extremely hydrophilic polyacrylate hydro-detergent fibres absorb the exudate, leading to swelling and subsequent gelation of the fibres themselves, maintaining the moist environment essential for healing and the ability to stimulate a mild autolytic debridement. In the meantime, the fibres mechanically disintegrate and attract with an electrostatic mechanism slough, fibrin, debris and bacteria, trapping them in the dressing and limiting bacterial proliferation, while allowing continuous but progressive cleansing and debridement of the base of the lesion and protecting the perilesional skin, thanks to a vertical absorption mechanism.
Furthermore, the gelation of the fibres allows the dressing not to adhere to the base of the lesion, allowing for atraumatic removal for the tissues and without pain for the patient, while maintaining a high cohesion of the dressing which allows removal in a single piece.
Finally, the composition of the dressing allows for the management of minor bleeding, thanks to its hemostatic properties.
The micro-adherent TLC layer in contact with the wound exudate, sees the formation of a lipid-colloidal gel, thanks to the interaction between the hydrocolloidal particles and Vaseline, which creates a moist environment favorable to the wound healing process, capable of stimulating the proliferation of key cells for tissue repair. The TLC matrix has been shown to stimulate the proliferation of fibroblasts by 70% and to increase the synthesis of hyaluronic acid and collagen production by 53% and 80% respectively. The lipid substances of the TLC matrix contribute to the non-adherence of the dressing to the base of the wound with consequent atraumatic dressing changes for the newly formed tissues and without pain for the patient. The ease of application and removal of the dressing, in addition to its effectiveness, has also been evaluated in clinical studies on thousands of patients.
Furthermore, the presence of sucrose octasulfate in the dressing gives it metalloproteinase modulating properties, allowing for better healing rates than the neutral dressing, with a consequent reduction in healing times, to the point of having allowed its inclusion in the NICE and IWGDF recommendations as a recommended dressing for the treatment of lower limb and diabetic foot lesions, by virtue of its cost-effectiveness.
In contact with wound exudate, the TLC-NOSF technology of UrgoStart Plus Pad gels. Thanks to this hydrophilic gelation and the presence of lipophilic substances in the composition, this technology:
- absorbs components of wound exudate, including enzymes called matrix metalloproteinases (MMPs), elevated levels of which have been linked to delayed healing of chronic wounds;
- maintains the moist environment necessary for wound healing.
Promoting debridement/cleansing:
- the fibers trap fibrin, slag, debris and cause them to detach from the wound when the dressing is removed.
Hemostatic properties:
- in case of small hemorrhages, the adsorption of plasma proteins by the polyacrylate fibers leads to the activation of coagulation and the adhesion of platelets, which initiate and have a synergistic effect on blood clotting.
Comfort promotion:
- the device is soft and flexible and the gelled TLC-NOSF technology lubricates the contact surface. These properties make the device conformable, reduce friction and make the device comfortable.
To ensure atraumatic removal of the lesion and peri-lesional skin and to allow easy removal:
- the moist environment prevents exudate from drying out. In addition, the gelled TLC-NOSF technology lubricates the contact surface, preventing the dressing from sticking to the wound bed when removed, so as not to resist removal and not to cause pain to the patient.
How to use
- The microadherent layer of UrgoStart may adhere to latex surgical gloves. It is therefore recommended to avoid contact or use sterile forceps.
- Cleanse the lesion with saline solution.
- If using an antiseptic, rinse the wound with saline solution before applying UrgoStart Plus Pad and dry the periwound skin.
- UrgoStart can be cut with sterile scissors to fit the size of the wound.
- The use of UrgoStart Plus does not replace mechanical debridement, if necessary.
- Remove the transparent protective films.
- Apply the micro-adherent side of UrgoStart Plus to the lesion.
- Keep the dressing in place with a secondary dressing, adhesive plaster or a bandage, including a compressive one if prescribed.
- UrgoStart Plus Pad may be left in place for up to 7 days, depending on clinical conditions and local protocol.
Warnings
Contraindications:
- known sensitivity to the medication or to one of its components;
- malignant lesions;
- fistula lesions;
- lesions from epidermiolysis bullosa;
- necrotic lesions.
- If clinical signs of local infection appear, treatment should be changed to antimicrobial therapy, according to medical advice.
- In case of atypical ulcers with signs of induration or excessive granulation, it is recommended to use UrgoStart Plus Pad only after having verified the absence of degeneration associated with the lesion, in order not to delay the diagnosis.
- At the beginning of treatment, a stinging/painful sensation may occur as a result of the activation of the healing process. This rarely leads to discontinuation of therapy.
- In the absence of clinical data as a first-line treatment of acute lesions and in the treatment of Epidermolysis Bullosa (even in case of long-standing lesions), the use of UrgoStart Plus Pad is not recommended.
- UrgoStart Plus Pad should not be used in a hyperbaric chamber.
- In the absence of specific clinical data, UrgoStart is not recommended for the treatment of lesions on children, pregnant or breastfeeding women.
- Concomitant use of creams, ointments or emulsions is not recommended.
- Do not use if package is damaged.
- Ensure that the sterile protection is intact before use. Do not use the dressing if damaged.
- Single use, do not resterilize the dressing.
Conservation
Store below 25°C and away from sources of light and humidity.
Validity with intact packaging: 36 months.
Format
Available in packs of 10 in sizes 6x6 cm and 10x10 cm.
Code 602892
Code 602893
